期刊文献+

局部晚期宫颈癌细胞中XPC、ERCC1的表达与新辅助化疗疗效的关系 被引量:2

Relationship between ERCC1,XPC proteins and curative effect of neoadjuvant chemotherapy in locally advanced cervical cancers
下载PDF
导出
摘要 目的:研究局部晚期宫颈癌(LACC)细胞中XPC、ERCC1的表达与宫颈癌新辅助化疗(NACT)敏感性的关系,为临床克服和预示NACT耐受提供研究资料。方法:选取1999年6月至2006年6月间在浙江大学医学院附属妇产科医院住院、临床诊断为Ib2~Ⅱb期的LACC患者77例,用免疫组化Envision二步法显示宫颈癌细胞中XPC和ERCC1的表达水平,并分析其及各种临床和病理参数与疗效的关系。结果:77例患者中有效60例,有效率为77.9%(60/77)。XPC和ERCC1蛋白表达免疫组化定位均在细胞核,显示LACC中NACT无效者XPC蛋白的表达强于有效者,差异有显著性(P<0.05);NACT无效者ERCC1蛋白的表达强于有效者,差异有显著性(P<0.01)。XPC、ERCC1蛋白表达存在高度一致,两者之间呈正相关(rs=0.418,P<0.01)。结论:局部晚期宫颈癌新辅助化疗具有较高的临床应用价值;XPC和ERCC1异常表达参与了局部晚期宫颈癌铂类耐受过程,异常上调表达的XPC和ERCC1蛋白可导致对铂类为基础NACT的耐受。 Objective: To analysis the protein expression of ERCC1. XPC and evaluate correlations among clinical, pathological, chemotherapy response variables and their prognostic value in locally advanced cervical cancer. Methods: Seventy seven continuous patients who was certified to be locally advanced cervical cancer were included. These patients underwent surgery after neoadjuvant chemotherapy from 1999 to 2006 in the Women Hospital,Zhejiang University,suffering from FIGO stage Ⅰb2 or Ⅱb disease of locally advanced cervical cancer. With immunohistochemical Envision two steps method staining of XPC and ERCC1 protein expression were performed on paraffin-embedded tissue sections. Results: XPC proteins expressed in the locally advanced cervical cancer cell nucleus. XPC proteins expression in the resistance for platinum-based chemotherapy of locally advanced cervical cancer were higher than those seen in the sensitivity for platinom-based chemotherapy of locally advanced cervical cancer, with X^2 equal to 8.741 and P equal to 0.015, rs equal to -0.277 and P equal to 0.015. It was regarded as significant difference. BRCC1 proteins overexpressed in the locally advanced cervical cancer cell nucleus. BRCC1 proteins expression in the resistance for platinum-hased chemotherapy of locally advanced cervical cancer were higher than those seen in the sensitivity for platinum-based chemotherapy of locally advanced cervical cancer, with X^2 equal to 12.616 and P equal to 0.006, rs equal to -0.329 and P equal to 0.003, regarded as significant difference. Coordinate expression of XPC and ERCC1 in the locally advanced cervical cancer. This relationship approximated a straight line with a Kappa of 0.368 and P=0.000. This suggested coordinate expression of these two genes. Conclusinn: The effective rate of neoadjuvant chemotherapy in locally advanced cervix cancer is 77.9%, and that indicates the neoadjuvant chemotherapy has clinical application value. Expression of XPC and BRCC1 proteins in locally advanced cervix cancer of re
出处 《温州医学院学报》 CAS 2008年第3期248-252,共5页 Journal of Wenzhou Medical College
关键词 ERCC1 XPC 核苷酸剪切修复 局部晚期宫颈癌 新辅助化疗 ERCC1 XPC nucleotide excision repair locally advanced cervical cancer neoadjuvant chemotherapy
  • 相关文献

参考文献21

  • 1Tierney J.Neoadjuvant chemotherapy for locally advanced cervical cancer:a systematic review and meta-analysis of individual patient data from 21 randomised trials[J]. Eur J Cancer,2003,39( 17):2470-2486. 被引量:1
  • 2Rosell R, Lord RV, Taron M, et al. DNA repair and cisplatin resistance in non-small-cell lung cancer [J]. Lung Cancer, 2002, 38(3) : 217- 227. 被引量:1
  • 3Reed E. Platinum -DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy[J]. Cancer Treat Rev,1998,24 (5) : 331-344. 被引量:1
  • 4Mamenta EL, Poma EE, Kaufmann WK, et al. Enhanced replicative bypass of platinum-DNA adducts in cisplatinresistant human ovarian carcinoma cell lines[J]. Cancer Res, 1994, 54 (13) : 3500-3505 . 被引量:1
  • 5Johnson SW, Perez RP, Godwin AK, et al. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines[J]. Biochem Pharmacol,1994, 47 (4): 689-697. 被引量:1
  • 6魏嘉,刘宝瑞,王亚平,钱晓萍.DNA修复基因单核苷酸多态性与铂类药物抵抗研究进展[J].中华肿瘤杂志,2006,28(3):161-163. 被引量:31
  • 7De Boer J,Hoeijmakers J H. Nucleotide excision repair and human syndromes[J]. Carcinogenesis,2000,21 (3) :453-460. 被引量:1
  • 8陈忠平,Areti MALAPETSA,Anne MONKS,Timothy G. MYERS,Gérard MOHR,Eaward A. SAUSVILLE,Dominic A. SCUDIERO,Lawrence C. PANASCI.人肿瘤细胞核苷酸切除修复蛋白表达与抗癌药耐药的相关性(英文)[J].癌症,2002,21(3):233-239. 被引量:12
  • 9周际昌.实用肿瘤内科学[M].北京:人民卫生出版社,2005:601~610. 被引量:150
  • 10Humphery PA,Wong AJ,vogelstein B,et al.Amplification and expression of EGFR gene in human glioma xenografts [J]. Cancer Res,1998;48:2231-2238. 被引量:1

二级参考文献78

  • 1王平,彭芝兰,张家文,刘辉,张崇淑,曹泽毅.子宫颈癌新辅助化疗中不同化疗途径的疗效比较[J].中华妇产科杂志,2005,40(4):227-230. 被引量:109
  • 2Aoki Y,Tomita M,Sato T,etal.Neoadjuvant chemotherapy for patients younger than 50 years with high-risk squamouscell carcinoma of the cervix.Gynecol Oncol,2001,83:263-267. 被引量:1
  • 3Benedetti-Panici P,Greggi S,Colombo A,et al.Neoadjuvant chemotherapy and radicalsurgery versus exclusive radiotherapy in locally advanced squamous cell cervicalcancer:results from the Italian multicenter randomized study.J Clin Oncol,2002,20:179-188. 被引量:1
  • 4Hwang YY,Moon H,Cho SH,et al.Ten-year survival of patients with locally advanced,stageⅠb-Ⅱb cervical cancer after neoadjuvant chemotherapy and radical hysterectomy.GynecolOncol,2001,82:88-93. 被引量:1
  • 5Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysisCollaboration.Neoadjuvant chemotherapy for locally advanced cervical cancer:a systematicreview and meta-analysis of individual patient data from 21 randomised trials.Eur JCancer,2003,39:2470-2486. 被引量:1
  • 6Tabata T,Takeshima N,Nishida H,et al.A randomized study of primarybleomycin,vincristine,mitomycin and cisplatin (BOMP) chemotherapy followed by radiotherapyversus radiotherapy alone in stage IIIB and IVA squamous cell carcinoma of thecervix.Anticancer Res,2003,23:2885-2890. 被引量:1
  • 7Duenas-Gonzalez A,Rivera L,Mota A,et al.The advantages of concurrent chemoradiationafter neoadjuvant chemotherapy for locally advanced cervical carcinoma.Arch MedRes,2002,33:201-202. 被引量:1
  • 8Manusirivithaya S,Chareoniam V,Pantusart A,et al.Comparative study of bulky stage IBand IA cervical cancer patients treated by radical hysterectomy with and withoutneoadjuvant chemotherapy:long-term follow-up.J Med Assoc Thai,2001,84:1550-1557. 被引量:1
  • 9Lin YS, Dowling AL, Quigley SD, et al. Co- regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. J Mol Pharmacol,2002,62( 1 ) :162-172. 被引量:1
  • 10Dai D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. J Pharmacogenetics ,2001,11 ( 7 ) :597-607. 被引量:1

共引文献268

同被引文献35

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部